Questa pagina è stata tradotta automaticamente e l'accuratezza della traduzione non è garantita. Si prega di fare riferimento al Versione inglese per un testo di partenza.

Functional Outcome of Organ Preservation After Neo-adjuvant Chemo Radiation for Rectal Cancer

17 settembre 2019 aggiornato da: Maastricht University Medical Center

Follow up and Functional Outcome of Organ Saving Treatment in Patients With Good Response to Neo-adjuvant (Chemo)Radiation for Rectal Cancer

The primary objective is to describe the functional outcome of patients that choose for organ saving treatment.

Panoramica dello studio

Descrizione dettagliata

Rectal cancer is a common form of cancer. Standard treatment for locally advanced rectal cancer is a long course of neoadjuvant radiation combined with chemotherapy (CRT) followed by resection. However, neoadjuvant CRT induces downsizing and downstaging, resulting in a complete response in 15-20% of the patients. In these patients surgery may be omitted. In the investigators previous study the investigators obtained good results with an organ saving treatment. Although the mortality and morbidity associated with radical surgery is avoided, the irradiated rectum remains in situ, possibly causing functional problems.

The primary objective is to describe the functional outcome of patients that choose for organ saving treatment. Functional outcome will be evaluated with questionnaires (quality of life) and manometric measurements (maximal resting pressure, maximal squeezing pressure, sphincter length, percentage asymmetry of the resting sphincter, sustained duration, length of the high pressure zone, rectoanal inhibitory reflex, rectal sensory threshold, and rectal compliance).

Secondary objectives include: the estimation of the cumulative risk of local failure within 5 years, the estimation of the cumulative risk of disease-free, distant-metastasis-free and overall survival within 5 years, determine the percentage of patients that chooses organ saving treatment instead of standard resection, determine the compliance to intensive follow-up, and compare the cost-effectiveness of organ saving treatment to standard surgical resection over a period of 5 years. These objectives will be assessed by frequent revision of the electronic patient file, as the patient is followed up to four times per year.

Study design: prospective observational registration study with 'invasive diagnostic procedures' Study population: The population will consist of patients, aged 18 years or older, with locally advanced rectal cancer who after chemoradiation have a clinical complete response (ycT0N0) or very good response (ycT1-2N0).

Main study parameters/endpoints: The main study endpoint is the functional outcome scores based on questionnaires and manometric measurements Nature and extent of the burden and risks associated with participation, benefit and group relatedness: The questionnaires take approximately 20 minutes to complete. There is a relatively low rate of side effects associated with manometric measurements. Results of this study will contribute to better understanding of functional complaints after rectal cancer treatment.

Tipo di studio

Osservativo

Iscrizione (Anticipato)

100

Contatti e Sedi

Questa sezione fornisce i recapiti di coloro che conducono lo studio e informazioni su dove viene condotto lo studio.

Luoghi di studio

      • Maastricht, Olanda, 6202 AZ
        • MUMC+

Criteri di partecipazione

I ricercatori cercano persone che corrispondano a una certa descrizione, chiamata criteri di ammissibilità. Alcuni esempi di questi criteri sono le condizioni generali di salute di una persona o trattamenti precedenti.

Criteri di ammissibilità

Età idonea allo studio

18 anni e precedenti (Adulto, Adulto più anziano)

Accetta volontari sani

No

Sessi ammissibili allo studio

Tutto

Metodo di campionamento

Campione non probabilistico

Popolazione di studio

The population will consist of patients, aged 18 years or older, with locally advanced rectal cancer who after chemoradiation have a clinical complete response (ycT0N0) or very good response (ycT1-2N0). Patients will be recruited from the outpatient clinic, by researchers or research nurses at Maastricht University Medical Center.

Descrizione

Inclusion Criteria:

  • 18 years old
  • Patients with primary rectal cancer without distant metastases who underwent CRT and show clinical complete response or very good response :

    • Clinical complete response (ycT0N0) after neo-adjuvant chemoradiation will be determined clinically (digital rectal examination, endoscopy) and radiologically (contrast-enhanced-MRI)
    • Very good response (ycT1-2N0) after neo-adjuvant chemoradiation will be determined clinically (digital rectal examination, endoscopy) and radiologically (contrast-enhanced-MRI). These patients will undergo a TEM to resect the small residual tumor
  • Comprehension of the alternative strategies and the concept of unknown risks are clear to the patient
  • Choosing for the organ-saving treatment option (wait&see policy or TEM)
  • Informed consent

Exclusion Criteria:

  • Unable to understand or read Dutch
  • Unwilling to comply to the questionnaires or manometric measurement.

Piano di studio

Questa sezione fornisce i dettagli del piano di studio, compreso il modo in cui lo studio è progettato e ciò che lo studio sta misurando.

Come è strutturato lo studio?

Dettagli di progettazione

Coorti e interventi

Gruppo / Coorte
Intervento / Trattamento
Study group
The population will consist of patients, aged 18 years or older, with locally advanced rectal cancer who after chemoradiation have a clinical complete response (ycT0N0) or very good response (ycT1-2N0).
  1. European Organisation for Research and Treatment of Cancer (EORTC) QLQ-30 questionnaire, version 3.0, Global Quality of Life Score
  2. Short Form (36) health survey
  3. EORTC CR38
  4. Vaizey score
  5. Low Anterior Resection Syndrome (LARS) score
  6. International Index of Erectile Function for men
  7. International Prostate Symptom Score for men
  8. Female Sexual Function Index for women
Manometry is a tool to measure the anal sphincter function. Patients do not need any bowel preparation before this procedure. During the examination a catheter tip will be positioned in the rectum above the sphincter and a small balloon will be inflated. This balloon is connected to a device that registers the measurements. Patients will receive instructions; e.g. squeeze, push, and cough. The procedure takes approximately 10 minutes and is not experienced as painful. Several parameters will be measured: the mean basal pressure, the maximum squeeze pressure, first sensation, first urge to defecate and the maximum tolerable volume. The manometric measurement will take place on the same day as the endoscopy and MRI (standard follow-up).

Cosa sta misurando lo studio?

Misure di risultato primarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Functional outcome
Lasso di tempo: 5 years

Functional outcome scores of patients that are treated with an organ saving strategy compared to patients who undergo the standard resection as described in literature.

Functional outcome will be evaluated with the following questionnaires:

  1. European Organisation for Research and Treatment of Cancer (EORTC) QLQ-30 questionnaire, version 3.0, Global Quality of Life Score
  2. Short Form (36) health survey
  3. EORTC CR38
  4. Vaizey score
  5. Low Anterior Resection Syndrome (LARS) score
  6. International Index of Erectile Function for men
  7. International Prostate Symptom Score for men
  8. Female Sexual Function Index for women

Functional outcome will be measured by manometric measurements:

  1. mean basal pressure (mmH2O)
  2. maximum squeeze pressure (mmH2O)
  3. first sensation (mL)
  4. first urge to defecate (mL)
  5. maximum tolerable volume (mL)
5 years

Misure di risultato secondarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Cumulative risk of local failure
Lasso di tempo: 5 years
All patients with a local recurrence will be excluded form further follow-up. This information will be based on an MRI of the lower abdomen in combination with endoscopy.
5 years
Cumulative risks of disease-free, distant-metastasis free and overall survival
Lasso di tempo: 5 years
5 years
The percentage of patients that choose the alternative strategies instead of traditional strategies and the motivation for their choice
Lasso di tempo: 3 years
3 years
The compliance to the intensive follow-up schedule
Lasso di tempo: 5 years
All patients are intended to participate in the standard follow-up schedule. Some of them may drop out due to other illness, ageing or other reasons. These patients will be included in the analysis as far as they participated.
5 years
Early detection of local failure (standard surgery still possible)
Lasso di tempo: 5 years
In the first year, every three months an MRI of the lower abdomen is made in combination with an endoscopy. From the second to the fifth year, these investigations will be done twice a year. With these short intervals, it is know that local recurence is detected in an early fase.
5 years

Collaboratori e investigatori

Qui è dove troverai le persone e le organizzazioni coinvolte in questo studio.

Collaboratori

Investigatori

  • Investigatore principale: Geerard L Beets, MD, PhD, Surgery, MUMC+
  • Cattedra di studio: Rianne CJ Beckers, MD, MSc, Surgery/Radiology MUMC+
  • Cattedra di studio: Miriam M van Heeswijk, MD, MSc, Surgery/Radiology MUMC+
  • Cattedra di studio: Monique Maas, MD, PhD, Radiology, MUMC+

Pubblicazioni e link utili

La persona responsabile dell'inserimento delle informazioni sullo studio fornisce volontariamente queste pubblicazioni. Questi possono riguardare qualsiasi cosa relativa allo studio.

Pubblicazioni generali

Studiare le date dei record

Queste date tengono traccia dell'avanzamento della registrazione dello studio e dell'invio dei risultati di sintesi a ClinicalTrials.gov. I record degli studi e i risultati riportati vengono esaminati dalla National Library of Medicine (NLM) per assicurarsi che soddisfino specifici standard di controllo della qualità prima di essere pubblicati sul sito Web pubblico.

Studia le date principali

Inizio studio

1 marzo 2014

Completamento primario (Effettivo)

1 ottobre 2017

Completamento dello studio (Anticipato)

1 settembre 2022

Date di iscrizione allo studio

Primo inviato

6 ottobre 2014

Primo inviato che soddisfa i criteri di controllo qualità

28 ottobre 2014

Primo Inserito (Stima)

30 ottobre 2014

Aggiornamenti dei record di studio

Ultimo aggiornamento pubblicato (Effettivo)

18 settembre 2019

Ultimo aggiornamento inviato che soddisfa i criteri QC

17 settembre 2019

Ultimo verificato

1 settembre 2019

Maggiori informazioni

Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .

Prove cliniche su Questionnaires for the evaluation of Quality of Life

Sottoscrivi